A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

NCT01790100 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: VX-135
DRUG: Ribavirin

Sponsor

Alios Biopharma Inc.

Collaborators

[object Object]